View 2 (Measuring Control) Consensus Statement: Postprandial Blood Glucose
Individuals with diabetes are at increased risk of developing microvascular complications (retinopathy, nephropathy, and neuropathy) and cardiovascular disease (CVD). The Diabetes Control and Complications Trial (DCCT) 1 and U.K. Prospective Diabetes Study (UKPDS) 2 showed that treatment programs resulting in improved glycemic control, as measured by HbA 1c , reduced the microvascular complications of diabetes. The effect of these treatment programs on reducing CVD was less clear. However, some epidemiological studies suggest that there may be a relationship between glycemic levels and CVD.
In the management of diabetes, health care providers usually assess glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, as well as by measuring HbA 1c . Therapeutic goals for HbA 1c and preprandial glucose levels have been established based on the results of controlled clinical trials. Unfortunately, the majority of patients with diabetes fail to achieve their glycemic goals. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control. Postprandial hyperglycemia is also one of the earliest abnormalities of glucose homeostasis associated with type 2 diabetes and is markedly exaggerated in diabetic patients with fasting hyperglycemia.
Several therapies targeted toward lowering PPG excursions are now available and have been shown to improve glycemic control as measured by HbA 1c . However, many questions remain unanswered regarding the definition of PPG and, perhaps most importantly, whether postprandial hyperglycemia has a unique role in the pathogenesis of diabetic complications and should be a specific target of therapy. To address these issues and to provide guidance to health care providers, the American Diabetes Association (ADA) convened a consensus development conference on 24-26 January 2001 in Atlanta, Georgia.
A seven-member panel of experts in diabetes, endocrinology, and metabolism heard selected abstracts and presentations from invited speakers. The panel was then asked to develop a consensus position on the following questions: The magnitude and time of the peak plasma glucose concentration depend on a variety of factors, including the timing, quantity, and composition of the meal. In nondiabetic individuals, plasma glucose concentrations peak ~60 min after the start of a meal, rarely exceed 140 mg/dl, and return to preprandial concentrations within 2-3 h. Even though glucose concentrations have returned to preprandial levels by 3 h, absorption of the ingested carbohydrate continues for at least 5-6 h after a meal.
Since people with type 1 diabetes have no endogenous insulin secretion, the time and height of peak insulin concentrations, and resultant glucose levels, are dependent on the amount, type, and route of insulin administration. In type 2 diabetic patients, peak insulin levels are delayed and are insufficient to control PPG excursions adequately. In type 1 and type 2 diabetic individuals, abnormalities in insulin and glucagon secretion, hepatic glucose uptake, suppression of hepatic glucose production, and peripheral glucose uptake all contribute to higher and more prolonged PPG excursions than in nondiabetic individuals.
Because the absorption of food persists for 5-6 h after a meal in both diabetic and nondiabetic individuals, the optimal time to measure postprandial glucose concentration must be determined. Practical considerations limit the number of blood samples that can be obtained. In general, a measurement of plasma glucose 2 h after the start of a meal is practical, generally approximates the peak value in patients with diabetes, and provides a reasonable assessment of postprandial hyperglycemia. Specific clinical conditions, such as gestational diabetes or pregnancy complicated by diabetes, may benefit from testing at 1 h after the meal.
QUESTION 2: What is the relationship among PPG, FPG, and HbA 1c ?
Hemoglobin A 1c is a measure of the degree to which hemoglobin is glycosylated in erythrocytes and is expressed as a percentage of total hemoglobin concentration. It reflects the exposure of erythrocytes to glucose in an irreversible and time-and concentration-dependent manner. HbA 1c levels provide an indication of the average blood glucose concentration during the preceding 2-3 months, incorporating both pre-and postprandial glycemia.
Because blood glucose concentrations vary widely during a 24-h period and from day to day in diabetes, the measurement of HbA 1c is the most accepted indicator of long-term glycemic control. However, the HbA 1c level does not provide a measure of the magnitude or frequency of shortterm fluctuations of blood glucose, which are particularly great in type 1 diabetes.
The relative contributions of FPG and PPG to HbA 1c have been studied only recently. Data from several large cohorts with either type 1 or type 2 diabetes were presented at the conference. In general, FPG, PPG, and especially mean plasma glucose (MPG) concentrations, defined by the average of multiple measurements of glucose taken throughout the day, are highly correlated with HbA 1c . In contrast, postprandial glucose excursions (PPGEs), defined as the change in glucose concentration from before to after a meal, and the incremental glucose area, defined as the area under the glucose curve above the premeal (or pre-oral glucose tolerance test [ In type 2 diabetes, a study performed in Pima Indians showed that correlations of HbA 1c with FPG and PPG measured 1 and 2 h after an oral glucose load or a test meal were indistinguishable (r = 0.6-0.7). Similar results from a European population were presented at the conference. In another study in type 2 diabetic patients, the effects of different glucose lowering therapies on the relationship among HbA 1c , FPG, and PPG were analyzed in a 24-week randomized clinical trial involving three treatment groups (a rapid-acting insulin secretagogue, an insulin sensitizer, and a combination of both agents) and a placebo group. FPG was found to correlate best with HbA 1c (r = 0.62-0.67); the correlation with PPG was weaker (r = 0.22-0.56) and was inconsistent across the three treatment and placebo groups. There was no significant correlation between HbA 1c and PPGE.
In summary, there are insufficient data to determine accurately the relative contribution of the FPG and PPG to HbA 1c . It appears that FPG is somewhat better than PPG in predicting HbA 1c , especially in type 2 diabetes. 
QUESTION 4: Under what circumstances should people with diabetes be tested for PPG?
The only setting in which PPG monitoring has been shown to improve outcomes is gestational diabetes. In one study, women with gestational diabetes were randomly assigned either to a treatment program in which therapy was adjusted to achieve predefined FPG and PPG levels or to one targeting premeal and bedtime glucose levels. 7 The women assigned A. Suspected postprandial hyperglycemia. In patients who achieve their premeal glucose targets, but whose overall glycemic control as determined by HbA 1c is inappropriately high, PPG monitoring and therapy to minimize PPGEs may be beneficial. B. Monitoring treatment aimed at specifically lowering PPG. In patients with type 1 or type 2 diabetes who are treated with glucoselowering agents expected primarily to reduce PPG, monitoring may be useful in titrating these treatments or in confirming that patients have in fact responded to the intervention. It is also possible that PPG monitoring may be beneficial to evaluate the effect of changes in nutrition or exercise patterns. C. Hypoglycemia. Hypoglycemia in the postprandial period is rare except in response to exercise or rapid-acting insulin analogs.
There are insufficient data either to support or to refute the need for extensive or routine PPG monitoring in diabetes, except in the setting of pregnancy. Since self-monitoring of blood glucose represents a significant financial and personal burden for patients, decisions regarding PPG monitoring should be based on the needs and responses of individual patients. The decision to recommend a glucose monitoring plan should be made judiciously, accompanied with specific patient education, and reviewed and modified regularly by the health care team. It has been suggested that agents that specifically lower PPG may decrease the risk of hypoglycemia and weight gain. These claims have not been consistently supported by randomized, controlled studies. There appear to be no unique risks associated with the specific lowering of PPG to achieve HbA 1c goals. There are several issues that should be considered when designing studies to examine PPG. Studies should be performed in well-defined patient groups; at a minimum, separation of patients by type of diabetes is necessary. It is also quite likely that results of studies in patients with impaired fasting glucose and/or impaired glucose tolerance may be different from those in patients with type 2 diabetes and different degrees of fasting hyperglycemia. In particular, elderly patients, in whom postprandial hyperglycemia may be the most prevalent abnormality in glucose homeostasis, may warrant special attention. In studies of the impact of PPG on diabetic complications, it is important to differentiate between microangiopathy and macroangiopathy as end points. Finally, attention must be paid to differences in therapeutic programs (e.g., nutrition therapy versus oral antihyperglycemic agents versus insulin) and type of oral glucose-lowering drugs used. Given these general principles, the following specific questions should be addressed:
A. How do we best assess postprandial hyperglycemia and the relationships among FPG, PPG, and Because CVD is the major cause of morbidity and mortality in patients with diabetes, and in type 2 diabetes in particular, understanding the impact on CVD events of treatments directed at specifically lowering PPG is crucial. Furthermore, the relationship between PPG excursions and both the wellestablished risk factors and the more recently identified putative mechanisms for CVD should be examined.
